Question 1

Is GLP-3 Reta FDA Approved? Current Research and Regulatory Status

Accepted Answer

GLP-3 Reta is not FDA approved as of 2024. Phase 2 data was published in the New England Journal of Medicine in 2023, and Phase 3 trials are underway. The compound remains classified as an investigational drug and is available only as a research peptide for in vitro laboratory use, not for clinical or therapeutic application.

Question 2

GLP-3 Reta's Clinical Development Timeline

Accepted Answer

Eli Lilly, the developing company, began Phase 1 studies of GLP-3 Reta (LY3437943) around 2020. Phase 1 results established initial safety and pharmacokinetic data in controlled research populations. Phase 2 followed with dose-ranging studies that enrolled several hundred participants across multiple cohorts over 48 weeks. The Phase 2 findings, published by Jastreboff and colleagues in the NEJM in July 2023, showed substantial reductions in body weight at the highest study doses. Those results accelerated interest in Phase 3 development. Lilly announced Phase 3 initiation in late 2023 under the program name TRIUMPH.

Question 3

What FDA Approval Requires

Accepted Answer

For any compound to receive FDA approval, it must complete Phase 3 trials demonstrating efficacy and safety in large, randomized controlled populations, then submit a New Drug Application (NDA) with the full data package. The FDA review process typically takes 6 to 12 months after submission. Phase 3 trials for GLP-3 Reta are multi-year studies, meaning approval timelines extend well beyond 2024. The Phase 2 data, while scientifically significant, represents an early stage in that approval pathway. It's worth noting that many compounds with promising Phase 2 data don't advance to approval.

Question 4

What Investigational Drug Status Means

Accepted Answer

While GLP-3 Reta is under active clinical investigation, it carries Investigational New Drug (IND) status. Outside of registered clinical trials, it cannot be prescribed or dispensed as a therapeutic agent. Research peptide suppliers sell it for in vitro laboratory research under separate regulatory frameworks governing research chemicals. Spartan Peptides supplies GLP-3 Reta as a lyophilized research compound with HPLC and mass spectrometry documentation. It is not represented as a pharmaceutical or clinical product.

Question 5

How Researchers Track Regulatory Status

Accepted Answer

The most reliable sources for current FDA status are the FDA's drug approval database (Drugs@FDA) and ClinicalTrials.gov, where Lilly's Phase 3 TRIUMPH trials are registered. Published review articles in journals like Obesity Reviews and Diabetes Care also provide updated summaries of the incretin compound landscape.

GLP-3(Reta) | Triple-Agonist Metabolic Research

NAD+ 750mg | Cellular Energy & DNA Repair Research

MOTS-c | Mitochondrial Metabolism Research Peptide

BPC-157 5mg | Tissue Repair & Gut Health Research

GLP-3 Reta FDA Status Frequently Asked Questions

Explore Full Research Index